Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection

NCT04706923 is registered in ClinicalTrials.gov with SymBio Pharmaceuticals as lead sponsor.

NCT NCT04706923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04706923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection
Lead sponsor
SymBio Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2021
Completion date
May 15, 2025
Enrollment
53 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus infections, cytomegalovirus infection